We are live on ! Find out more

203 hedge funds and large institutions have $3.46B invested in Insmed in 2021 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 89 increasing their positions, 51 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 51

38% more call options, than puts

Call options by funds: $4.59M | Put options by funds: $3.33M

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

3.62% more ownership

Funds ownership: 103.46%107.08% (+3.6%)

2% more funds holding

Funds holding: 199203 (+4)

5% less capital invested

Capital invested by funds: $3.63B → $3.46B (-$174M)

Holders
203
Holders Change
+4
Holders Change %
+2.01%
% of All Funds
3.52%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
30
Increased
89
Reduced
51
Closed
24
Calls
$4.59M
Puts
$3.33M
Net Calls
+$1.26M
Net Calls Change
+$406K

INSM Hedge Fund Activity: Q2 2021 in Review

203 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2021, worth a combined $3.46B — down 4.8% from $3.63B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new INSM positions and 24 closed out — a net gain of 6 holders — while 89 added to existing stakes and 51 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $91.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $62.3M.

  • 203 institutional investors held Insmed (INSM) as of Q2 2021, up from 199 in Q1 2021.
  • Funds reported $3.46B of Insmed stock for Q2 2021, down 4.8% quarter-over-quarter.
  • 30 funds opened new Insmed positions in Q2 2021 and 24 closed out, a net change of +6 holders.
  • The largest Insmed buyer in Q2 2021 was T. Rowe Price Associates, an estimated $91.1M added.
  • The largest Insmed seller in Q2 2021 was Lord, Abbett & Co, an estimated $62.3M sold.

Based on aggregated 13F filings for Q2 2021.